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Ulcerative colitis (UC) involves chronic inﬂammation of the large intestine. Several agents are used to
treat UC, but adverse side effects are remaining problems. We examined the effect of tropisetron as a new
type of drug for UC using a dextran sulfate sodium (DSS)-induced model of colitis in mice. We developed
a DSS-induced model of colitis and calculated the Disease Activity Index and colon length. We measured
myeloperoxidase activity and determined the protein level and mRNA level of cytokines in the colon.
DSS-induced colitis was ameliorated by administration of tropisetron and PNU282987. Pre-
administration of methyllycaconitine diminished the suppressive effect of tropisetron upon DSS-
induced colitis. These ﬁndings suggested that a7 nicotinic acetylcholine receptors (a7 nAChRs) were
related to the suppressive effect of tropisetron on DSS-induced colitis. Additionally, stimulation of a7
nAChRs decreased the colon level of interleukin-6 and interferon-g upon DSS administration. Further-
more, stimulation of a7 nAChRs decreased macrophage inﬁltration, with expression of a7 nAChR
increased by DSS administration. These results suggest that the underlying mechanism of this sup-
pressive effect on DSS-induced colitis is via stimulation of a7 nAChRs and involves suppression of
expression of pro-inﬂammatory cytokines. Tropisetron could be a new type of therapeutic agent for UC.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Ulcerative colitis (UC) is a chronic relapsing and remitting in-
ﬂammatory condition in the large intestine. Diarrhea and bloody
stools are typical symptoms of UC. The number of UC patients in
Europe, the USA, and Asia has been increasing year by year (1e3).
The etiology and pathogenesis of UC have not been deﬁned fully.
However, genetic and environmental factors (e.g., ﬂora in the
lumen of the intestine) are considered to cause aberrant immune
disorders (1e5). In particular, inﬂammatory cells such as neutro-
phils and macrophages inﬁltrate the colonic mucosa and produce a
large variety of inﬂammatory cytokines (e.g., interleukin (IL)-6).
Such cytokine release causes activation of inﬂammatory cells and).
rmacological Society.
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d/4.0/).damage to colon tissue, and results in further inﬁltration of in-
ﬂammatory cells (1,2,5). Stopping this negative spiral is a key
strategy for UC treatment. 5-aminosalicylic acid, glucocorticoids,
immunosuppressants, and inﬂiximab are used for UC treatment.
However, several side effects of these agents affect the quality of life
of patients, and these drugs cannot produce complete remission in
all patients (1e4,6). Hence, new types of drugs are desired for the
treatment of UC.
Epidemiologic evidences suggest that cigarette smoking is
negatively associated with UC. Nicotine was expected to be a
therapeutic agent for UC but the mechanism of this effect is
incompletely understood (7,8). In fact, the effect of nicotine
administration via oral, rectal, and transdermal routes on UC has
been shown in clinical studies. However, use of nicotine is limited
by its side effects of nausea and headache (9e11).
Stimulation of the vagus nerve attenuates the systematic in-
ﬂammatory response (12). Stimulation of a7 nicotinic acetylcholinenese Pharmacological Society. This is an open access article under the CC BY-NC-ND
Y. Tasaka et al. / Journal of Pharmacological Sciences 127 (2015) 275e283276receptors (a7 nAChRs) on macrophages has anti-inﬂammatory ef-
fects via the vagus nerve (13). In a murine model of UC, vagotomy
has been shown to aggravate the development of dextran sodium
sulfate (DSS)-induced colitis, and nicotine diminishes this effect
(14). Electrical stimulation of the vagus nerve has suppressive effect
on trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats (15).
Furthermore, a7 nAChR-deﬁcient mice are not affected by stimu-
lation of a7 nAChRs or vagotomy with regard to the inﬂammatory
response caused by DSS treatment (16). These evidences suggest
that the cholinergic anti-inﬂammatory pathway via a7 nAChRs is a
potential target of drug development for UC.
The 5-hydroxytryptamine-3 receptor (5-HT3R) antagonist tro-
pisetron is used as an antiemetic drug for chemotherapy, and has
been reported to have anti-inﬂammatory effects. Tropisetron in-
hibits expression of tumor necrosis factor (TNF)-a and IL-1b in
lipopolysaccharide (LPS)-stimulated primary human monocytes
(17), and inhibits the gene transcription and synthesis of IL-2 in
stimulated human T-cells (18). In an animal model of colitis in rats,
tropisetron was found to suppress acetic acid- (19) and TNBS-
induced colitis (20). These studies suggested that the anti-
inﬂammatory effects of tropisetron are via inhibition of 5-HT3Rs.
Tropisetron has been found to be a partial agonist of a7 nAChRs
(21). This evidence is very important for understanding the
mechanism of the anti-colitis effect of tropisetron. Also,Fig. 1. Effect of tropisetron on development of DSS-induced colitis. 6 week old mice were tre
n ¼ 10, or 1 mg/kg; n ¼ 10, or 2 mg/kg; n ¼ 9) once daily. Disease Activity Index was measure
the end of the experimental period. Statistical signiﬁcances versus normal (n ¼ 5) or DSS (n ¼
colon and MPO activity). Values are mean ± S.E.M. **, P < 0.01 (versus normal), #, P < 0.05involvement of a7 nAChRs in the anti-inﬂammatory effect of tro-
pisetron has not been studied. Tropisetron could be a safe and
beneﬁcial anti-inﬂammatory drug for the treatment of UC. Here, we
examined the effect of tropisetron on the development of DSS-
induced colitis in mice.
2. Materials and methods
2.1. Chemicals
DSS (molecular weight, 5000; sulfur content, 15e20%),
hydrogen peroxide, and Mildform were obtained from Wako Pure
Chemicals (Osaka). Tropisetron, hexadecyltrimethylammonium
(HTAB), O-dianisidine dihydrochloride, and myeloperoxidase
(MPO) from human leukocytes were purchased from Sigma-
eAldrich (Saint Louis, MO, USA). PNU282987 and methyl-
lycaconitine were obtained from Tocris Bioscience (Bristol, UK).
FSC22was purchased from Leica Biosystems (Saint Louis, MO, USA).
a-bungarotoxin, Alexa Fluor 488 Conjugate, Alexa Fluor 594 Anti-
goat Anti-rat Immunoglobulin (Ig)G, and ProLong® Gold Antifade
Reagent with Diamidino-2-phenylindole (DAPI) were obtained
from Life Technologies Japan (Tokyo). Anti-CD11b antibody was
purchased from Abcam (Cambridge, UK). Mouse IL-1 beta ELISA
Ready-SET-Go!® and each enzyme-linked immunosorbent (ELISA)ated with 5% DSS for 7 days, and intraperitoneally administered tropisetron (0.5 mg/kg;
d daily (A). The length of the colon (B) and colonic MPO activity (C) were determined at
10) were calculated by Steel's test (Disease Activity Index) or Dunnett's test (Length of
or ##, P < 0.01 (versus DSS) were considered signiﬁcant.
Fig. 2. Effect of tropisetron on the level of injury in the mucosa of DSS-treated mice. 6
week old ICR mice were treated with 5% DSS for 7 days, and intraperitoneally
administered tropisetron (1 mg/kg) once daily. Colonic tissue samples were ﬁxed in
Mildform, then embedded in parafﬁn before being cut into 4 mm sections, and sub-
jected to histological examination by hematoxylin and eosin staining.
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eBioscience (San Diego, CA, USA). An RNeasy Plus Universal Mini kit
was purchased from Qiagen (Valencia, CA, USA). A PrimeScript RT
Reagent Kit with gDNA Eraser, Mouse Housekeeping Gene Primer
Set, SYBR Premix Ex Taq II, and primers for Actb and Ywhaz were
obtained from Takara Bio (Shiga).
2.2. Animals
Wild-type male ICR mice were purchased from Japan SLC (Shi-
zuoka). Experiments were conducted according to guidelines set by
the Ethics Committee for Animal Experimentation of Ehime Uni-
versity Medical School.
2.3. Development of DSS-induced colitis and measurement of the
Disease Activity Index (DAI) and colon length
DSS-induced colitis was induced in mice by addition of 5% DSS
(w/v, ﬁnal concentration) to their drinking water, as described
previously (22). Tropisetron and methyllycaconitine (selective
antagonist of a7 nAChRs) were dissolved in 0.9% (physiological)
saline. PNU282987 (selective agonist of a7 nAChRs) was dissolved
in 1% dimethyl sulfoxide. In the DSS alone-treated group, these
solvents were administrated as vehicle control, respectively. Tro-
pisetron, methyllycaconitine, and PNU282987 were administered
via the intraperitoneal route once daily. The ﬁrst administration of
tropisetron, PNU282987 and methyllycaconitine was done just
before the start of DSS administration, and methyllycaconitine was
administered 30 min before administration of tropisetron. Mice
were allowed free access to DSS-containing water for 7 days. The
severity of DSS-induced colitis was monitored by the DAI, colon
length, MPO activity, and histologic analyses. The DAI was deter-
mined macroscopically once a day by an observer unaware of the
treatment the mice had received according to criteria reported
previously (22). In brief, the DAI was calculated as the sum of a
diarrhea stool score (0, normal stool; 1, mildly soft stool; 2, very soft
stool; 3, watery stool) and a bloody stool score (0, normal-colored
stool; 1, brown stool; 2, reddish stool; 3, bloody stool). At the end
of the protocol, animals were killed by cervical dislocation. Colons
were dissected, their length from the ileocecal junction to the anal
vergemeasured and used as amorphometric measure of the degree
of inﬂammation.
2.4. Assay for measurement of MPO activity
MPO activity in colon tissue was calculated by a method
described previously (22) with some modiﬁcation, and used as
indicator of leukocyte inﬁltration. After DSS treatment, colons
were dissected, rinsed with cold 0.9% saline, and cut into small
pieces. Then, tissue extracts were prepared by homogenization in
50 mM phosphate buffer with 0.5% (w/v) HTAB. Supernatants were
collected after centrifugation (15,000 rpm, 10 min, 4 C). MPO
activity was determined in 5 mM phosphate buffer with 0.5 mM
O-Dianisidine, 0.00005% (w/v) hydrogen peroxide, and 1 mg of
protein. MPO activity was obtained from the slope of the reaction
curve. Speciﬁc activity was expressed as the number of molecules
of hydrogen peroxide converted per 5 min per milligram of
protein.
2.5. Histologic and immunohistochemical (IHC) analyses
Histologic analyses were conducted using hematoxylin & eosin
(H&E) staining by a method described previously (23) with some
modiﬁcation. After DSS treatment, colons were dissected, rinsed
with cold 0.9% saline, and ﬁxed in Mildform. Next, colon sampleswere embedded in parafﬁn before being cut into sections (thick-
ness, 4 mm). For histologic examination, sections were stained ﬁrst
with Mayer's hematoxylin, and then with eosin solution. Samples
were mounted with mounting medium and inspected with the aid
of an Eclipse 50i microscope (Nikon, Tokyo, Japan). IHC analyses
were also carried out in colon samples after DSS treatment. First,
colons were dissected, rinsed with cold 0.9% saline, and embedded
immediately in FSC22 with dry iceeacetone. Next, colon samples
were cut into sections (thickness, 5 mm) and ﬁxed in acetone. Then,
samples were incubated with a-bungarotoxin, Alexa Fluor 488
Conjugate (20 mg/mL, 4 C, 12 h), anti-CD11b antibody (100-fold
dilution, 4 C, 12 h), and Alexa Fluor 594 Anti-goat Anti-rat IgG
(500-fold dilution, room temperature, 1 h) in this order. After
mounting with ProLong Gold Antifade Reagent with DAPI, sections
were inspected with the aid of a BZ-9000 microscope (Keyence,
Osaka, Japan). Anti-CD11b antibody and a-bungarotoxin double
positive cells that were observed in 10 mm length of mucosal
sections from anal verge were counted.
2.6. Determination of the protein level of cytokines in the colon and
serum
After DSS treatment, colons were dissected, rinsed with cold
(0.9%) saline, cut into small pieces, and tissue extracts prepared by
homogenization in phosphate-buffered saline. Supernatants were
collected after centrifugation (15,000 rpm, 10 min, 4 C). After DSS
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tained by centrifugation (3000 rpm, 15 min, 4 C). Protein levels of
cytokines were determined by ELISA according to manufacturer
protocols.
2.7. Determination of the mRNA level of cytokines in the colon
Colons were dissected 4 days after starting DSS treatment and
stored at 80 C until extraction of total RNA. Tissues were dis-
rupted by homogenization, and total RNA extracted using an
RNeasy Plus Universal Mini Kit. Then, samples (1 mg of RNA) were
reverse-transcribed with a PrimeScript RT Reagent Kit with gDNA
Eraser according to manufacturer protocols. Quantiﬁcation of TNF-
a transcripts was done with SYBR Premix Ex Taq II and a 7500 Real-
Time PCR System (Applied Biosystems, Foster City, CA, USA) using
the DDTC method. Internal control genes to normalize quantities of
cDNA were determined to be Actb and Ywhaz using the Mouse
Housekeeping Gene Primer Set. Primers for TNF-a were designed
according to a previous report (22). The primers used (forward and
reverse, respectively) were: Actb, 50-CATCCGTAAA-
GACCTCTATGCCAAC-30 and 50-ATGGAGCCACCGATCCACA-30;
Ywhaz, 50-ACAATGTTCTTGGCCCATGTGA-30 and 50-ATCCCAGGCA-
GACTGTAAGAGCA-30; Tnf-a, 50-CGTCAGCCGATTTGCTATCT-30 andFig. 3. Effect of PNU282987 on development of DSS-induced colitis. 6 week old ICR mice
(0.25 mg/kg; n ¼ 10, or 0.5 mg/kg; n ¼ 13, or 1 mg/kg; n ¼ 13) once daily. Disease Activity
were determined at the end of the experimental period. Statistical signiﬁcances versus nor
Dunnett's test (Length of colon and MPO activity). Values are mean ± S.E.M. **, P < 0.01 (v50-CGGACTCCGCAAAGTCTAAG-30. Speciﬁcity was conﬁrmed by in-
clusion of reverse transcriptase-free controls.
2.8. Statistical analyses
Data are the mean ± SEM. Two-way analysis of variance fol-
lowed by Steel's test or Dunnett's test, or the Tukey test for un-
paired results, were used to evaluate differences between more
than three groups. P < 0.05 was considered signiﬁcant.
3. Results
3.1. Effect of tropisetron on the development of DSS-induced colitis
We examined the effect of tropisetron on the development of
colitis induced by administration of 5% DSS. There was no signiﬁ-
cant difference in the volume of water consumed by each group of
mice (data not shown). Administration of 5% DSS increased the DAI,
and the increase was suppressed signiﬁcantly by tropisetron
administration in a dose-dependent manner (Fig. 1A). DSS-induced
colon shortening and colonic MPO activity were ameliorated
signiﬁcantly by tropisetron administration (Fig. 1B, C). Crypt loss
and leukocyte inﬁltration were observed in DSS-treated micewere treated with 5% DSS for 7 days, and intraperitoneally administered PNU282987
Index was measured daily (A). The length of the colon (B) and colonic MPO activity (C)
mal (n ¼ 5) or DSS (n ¼ 10) were calculated by Steel's test (Disease Activity Index) or
ersus normal), #, P < 0.05 or ##, P < 0.01 (versus DSS) were considered signiﬁcant.
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by tropisetron administration (Fig. 2).
3.2. Involvement of stimulation of a7 nAChRs in the suppressive
effect of tropisetron on DSS-induced colitis
We undertook two experiments to examine involvement of
stimulation of a7 nAChR in the suppressive effect of tropisetron
on DSS-induced colitis. First, we examined the effect of
PNU282987 on DSS-induced colitis. The DAI increase induced by
DSS administration was ameliorated signiﬁcantly by PNU282987
administration (Fig. 3A). The colon length and MPO activity
aggravated by DSS administration were also ameliorated signiﬁ-
cantly by PNU282987 administration (Fig. 3B, C). In contrast,
PNU282987 did not affect the defecation of normal mice (data
not shown).
Next, we examined the combination effect of methyl-
lycaconitine and tropisetron to understand the involvement of a7
nAChRs and 5-HT3Rs. Methyllycaconitine (1 mg/kg) alone did not
affect DSS-induced colitis (Fig. 4AeC). Pre-administration of
methyllycaconitine diminished the suppressive effect ofFig. 4. Effect of methyllycaconitine on suppressive effect of tropisetron on development o
intraperitoneally administered methyllycaconitine (MLA) and/or tropisetron once daily. Dise
activity (C) were determined at the end of the experimental period. Statistical signiﬁcances
MLA and tropisetron (n ¼ 14e19) were calculated by Tukey's test. Values are mean ± S.E.M.
tropisetron) were considered signiﬁcant. n.s., not signiﬁcant.tropisetron (1 mg/kg) in terms of the DAI and colon length (Fig. 4A,
B), but did not affect MPO activity (Fig. 4C).
3.3. Effect of stimulation of a7 nAChRs on levels of proteins and
mRNA of cytokines
We investigated the effect of stimulation of a7 nAChRs on
expression of inﬂammatory cytokines in DSS-induced colitis.
Stimulation of a7 nAChRs was demonstrated by administration of
PNU282987 (1 mg/kg). Administration of 5% DSS increased the
protein level of IL-1b, IL-6 and IFN-g in colon tissue. The increase
of expression of IL-6 and IFN-g was decreased signiﬁcantly by
PNU282987 administration. The protein level of TNF-a in colon
tissue was not affected by the administration of 5% DSS or
PNU282987 (Fig. 5AeD). We studied the effect of stimulation of a7
nAChRs on the serum protein level and colonic mRNA level of TNF-
a to reveal the involvement of this cytokine. DSS administration
signiﬁcantly increased the serum protein level and colonic mRNA
level of TNF-a. However, stimulation of a7 nAChRs by PNU282987
administration did not affect the serum protein level and colonic
mRNA level of TNF-a (Fig. 5E, F). Upon real-time RT-PCR, we foundf DSS-induced colitis. 6 week old ICR mice were treated with 5% DSS for 7 days, and
ase Activity Index was measured daily (A). The length of the colon (B) and colonic MPO
versus normal (n ¼ 5), DSS (n ¼ 15e20), MLA (n ¼ 15e20), tropisetron (n ¼ 15e20), or
**, P < 0.01 (versus normal), #, P < 0.05 or ##, P < 0.01 (versus DSS), y, P < 0.05 (versus
Fig. 5. Effect of stimulation of a7 nAChR on the protein and mRNA levels of cytokines. 6 week old ICR mice were treated with 5% DSS for 7 days, and intraperitoneally administered
PNU282987 (1 mg/kg; n ¼ 8) once daily. Colonic and serum samples ware prepared according to the method described in Materials & Methods. And the protein levels of IL-1b (A),
IL-6 (B), IFN-g (C), colonic TNF-a (D), and serum TNF-a (E) were determined by ELISA. The colonic mRNA level of TNF-a (F) was determined by real-time RT-PCR method with the
samples of day4 according to the manner written in the material method. Relative expression shown in Fig. 5F was calculated with Actb as an internal control. Statistical sig-
niﬁcances versus normal (A-E; n ¼ 5, F; n ¼ 8) and DSS (n ¼ 8) were calculated by Tukey's test. Values are mean ± S.E.M. *, P < 0.05 or **, P < 0.01 (versus normal), #, P < 0.05 or ##,
P < 0.01 (versus DSS) were considered signiﬁcant. n.s., not signiﬁcant.
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ampliﬁed.
3.4. Effect of stimulation of a7 nAChRs on the extent of macrophage
proliferation in the mucosa of the large intestine
We undertook IHC analyses with antibodies against CD11b and
a-bungarotoxin (selective antagonists of a7 nAChR) to conﬁrm the
existence of expression of a7 nAChRs in the large intestine.
Expression of anti-CD11b antibody-positive cells (red) was
observed mainly in the submucosa of the large intestine, and
expression of a-bungarotoxin-positive cells (green) was observed
in the submucosa of the large intestine. DSS administration mark-
edly increased the number of anti-CD11b antibody-positive cells
and a-bungarotoxin-positive cells. Stimulation of a7 nAChRs
markedly decreased the number of anti-CD11b antibody-positive
cells and a-bungarotoxin-positive cells that had been increased by
DSS administration. Furthermore, almost all of the a-bungarotoxin-
positive cells were also positive to anti-CD11b antibody (yellow)
(Fig. 6A). We also measured the number of a-bungarotoxin and
anti-CD11b antibody double positive cells as macrophages with a7
nAChRs. Administration of DSS signiﬁcantly increased the number
of macrophages with a7 nAChRs, and simulation of a7 nAChRs by
PNU282987 administration signiﬁcantly suppressed this effect
(Fig. 6B).
4. Discussion
We demonstrated the effect of tropisetron on DSS-induced co-
litis in this study. Administration of tropisetron ameliorated thedevelopment of DSS-induced colitis in various index parameters in
a dose-dependent manner. These ﬁndings suggest that tropisetron
could be a candidate therapeutic agent for UC. Additionally, the
effective dose of tropisetron showed in Figs. 1 and 2 was similar to
that reported to ameliorate colitis in other animal models (19, 20).
Such observations suggest that the dose used in the present study
would enable tropisetron to elicit its anti-colitis effects. Tropisetron
assumes the dual role of a selective agonist of a7 nAChRs and a
selective antagonist of 5-HT3Rs (21). However, which of these two
mechanisms is important for the suppressive effect of tropisetron
on DSS-induced colitis is incompletely understood. Therefore, we
next investigated the effect of PNU282987 and methyllycaconitine
on DSS-induced colitis to reveal involvement of a7 nAChRs in the
mechanism of the anti-colitis effect of tropisetron. Administration
of PNU282987 also ameliorated the development of DSS-induced
colitis to the same extent as that seen with tropisetron (Fig. 3).
These results suggest that an agonist of a7 nAChRs could be a
therapeutic agent for UC. On the other hand, Pre-administration of
methyllycaconitine diminished the anti-colitis effect of tropisetron
on the DAI and colon length. However, MPO activity was not
affected by pre-administration of methyllycaconitine (Fig. 4). This
result suggests that stimulation of a7 nAChRs has an important role
in suppression of DSS-induced colitis, as well as the potency of
other underlying anti-inﬂammatory mechanism. Ondansetron
(antagonist of 5-HT3Rs) has been reported to inhibit
lipopolysaccharide-stimulated secretion of TNF- a in human
monocytes (17). Tropisetron inhibits both IL-2 gene transcription
and IL-2 synthesis in stimulated T cell (18). Moreover, several an-
tagonists of 5-HT3Rs (e.g. tropisetron, granisetron) have been re-
ported to ameliorate animalmodel of colitis via suppression of anti-
Fig. 6. Effect of stimulation of a7 nAChR on the level of macrophage proliferation and expression of a7 nAChR in the intestinal mucosa. 6 week old ICR mice were treated with 5% DSS
for 7 days, and intraperitoneally administered PNU282987 (1 mg/kg) once daily. Colonic tissue samples were dissected, ﬁxed in acetone, then being cut into 5 mm sections, and
subjected to immunohistochemical staining with DAPI, anti-CD11b antibody, and a-bungarotoxin according to the manner written in the material method (A). Arrows mean anti-
CD11b antibody and a-bungarotoxin double positive cells. Anti-CD11b antibody and a-bungarotoxin double positive cells were also measured according to the manner written in
the material method (n ¼ 3) (B). Statistical signiﬁcance was calculated by Tukey's test. Values are mean ± S.E.M. *, P < 0.05 (versus normal), ##, P < 0.01 (versus DSS) were considered
signiﬁcant.
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These studies support the notion that tropisetron has anti-
inﬂammatory effects due to inhibition of 5-HT3Rs. Taken together,
these evidences also suggest that tropisetron has at least two
mechanisms of anti-inﬂammatory effects on colitis: simulation of
a7 nAChRs and inhibition of 5-HT3Rs. Ondansetron could not
stimulate a7 nAChRs (21). This suggests that dual anti-
inﬂammatory mechanism may be characteristic speciﬁc for tropi-
setron among the antagonist of 5-HT3Rs.Studies have suggested the involvement of pro-inﬂammatory
cytokines (e.g., TNF-a, IL-1b, IL-6) on suppression of DSS-induced
colitis via the vagal nerve system (14). Tropisetron ameliorates
animal colitis model by suppression of TNF-a, IL-1b, and IL-6 (19,
20). On the other hand, Figs. 3 and 4 suggest that tropisetron has
a potency to be an anti-inﬂammatory agent with dual pathway
(simulation of a7 nAChRs and inhibition of 5-HT3Rs). Hence, we also
investigated the effect of stimulation of a7 nAChRs on expression of
pro-inﬂammatory cytokines in colon tissue to understand the
Y. Tasaka et al. / Journal of Pharmacological Sciences 127 (2015) 275e283282mechanism of the anti-colitis effect of stimulation of a7 nAChRs in
DSS-induced colitis. DSS administration signiﬁcantly increased the
protein level of IL-1b, IL-6 and IFN-g, and this was similar to the
previous reports (25,26). Conversely, the protein level of TNF-awas
not affected by administration of DSS and PNU282987. TNF-a is
considered to play an important part in the development of DSS-
induced colitis and UC. Thus, we demonstrated serum protein
and colonic mRNA level of TNF-a, and observed a signiﬁcant in-
crease upon DSS administration in this model of colitis. These re-
sults may be due to the effect of the TNF-a produced in intestinal
tissue being secreted rapidly into blood. Stimulation of a7 nAChRs
suppressed the colonic protein levels of IL-6 and IFN-g. This result
suggests that involvement of IL-6 and IFN-g is downstream of the
ameliorative effect of DSS-induced colitis via stimulation of a7
nAChRs. Conversely, it seems that IL-1b and TNF-a were not
involved in the ameliorative effect of DSS-induced colitis via
stimulation of a7 nAChRs upon PNU282987 administration. Indeed,
electrical stimulation of the vagus nerve decreases serum levels of
TNF-a (13). This disparity in data may have been due to differences
in the manner of stimulation of a7 nAChRs (electrical stimulation vs
medicinal stimulation).
Studies have reported that tyrosine kinase Jak2 interacts directly
with nicotine-activated a7 nAChRs, and then phosphorylates the
signal transducer and activator of transcription 3 (STAT3) in mac-
rophages. Additionally, STAT3 is not directly related to production
of pro-inﬂammatory cytokines, and the attenuated expression of
cytokines mediated by stimulation of a7 nAChRs is considered to be
caused by collaboration between nuclear factor-kappa B (NF-kB)
and the Jak/STAT pathway. LPS of enteric bacteria is recognized by
toll-like receptor 4, and promotes the production of inﬂammatory
cytokines through phosphorylation of NF-kB downstream, and
exacerbates inﬂammation (27). Activated macrophages can pro-
duce IL-6 through NF-kB activation, which results in activation of
T-cells (5). Furthermore, activated T-cells produce IFN-g, which
promotes further inﬂammation (28). In the present study, stimu-
lation of a7 nAChRs decreased the protein level of IL-6 and IFN-g in
colon tissue that was increased by DSS administration. This ﬁnding
suggests that IL-6 and IFN-g have important roles in the suppres-
sive effect of DSS-induced colitis by stimulation of a7 nAChRs. We
hypothesized that stimulation of a7 nAChRs may suppresses DSS-
induced colitis through the Jak/STAT pathway in colonic macro-
phages in the model described here. Studies have shown expres-
sion of a7 nAChRs on macrophages in vitro (13) and in the small
intestine (29). However, expression of a7 nAChRs on colonic mac-
rophages in a colitis model is incompletely understood. Therefore,
we investigated expression of a7 nAChRs and macrophage inﬁl-
tration into the large intestine in a DSS-induced model of colitis
using IHC analyses. Macrophages with expression of a7 nAChRs
were observed in control samples, and DSS administration
increased macrophage inﬁltration with expression of a7 nAChRs
into the submucosal layer of the large intestine. This result suggests
that colonic macrophages can be a target of tropisetron to exert
anti-inﬂammatory effects on DSS-induced colitis via stimulation of
a7 nAChRs. Furthermore, stimulation of a7 nAChRs decreased
macrophage inﬁltration into the colonic mucosa caused by DSS
administration. Stimulation of vagus nerve attenuates systemic
inﬂammatory response (12). Vagotomy has been reported to
aggravate development of DSS-induced colitis, and nicotine di-
minishes the effect of vagotomy (14). This observation suggests that
supplementation of ACh in colonic macrophages via the vagus
nerve is responsible for cholinergic anti-inﬂammatory effects.
Stimulation of a7 nAChRs result in suppression of IL-6 and IFN-g
(Fig. 5). Taken together, stimulation of a7 nAChRs may suppress
further activation of macrophages via suppression of IFN-g due to
inhibition of T-cells activation due to IL-6 suppression.Tropisetron has been used as an antagonist of 5-HT3Rs in clinical
practice; very few adverse drug reactions have been noted. Here,
we investigated the effect of tropisetron and stimulation of a7
nAChRs on DSS-induced colitis. Our ﬁndings suggest involvement
of the stimulation of a7 nAChRs in the anti-inﬂammatory effects of
tropisetron apart from antagonism of 5-HT3Rs. These dual anti-
inﬂammatory mechanisms support the notion that tropisetron
could be a safe and beneﬁcial new type of therapeutic agent for UC.
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